Study Overview: This study is testing a new treatment called GLSI-100, which is a type of immunotherapy. Immunotherapy helps the body's immune system fight cancer. The study is for people with HER2/neu positive breast cancer, a type of cancer where certain proteins grow more than usual. Participants will receive injections under the skin over 6 months, followed by additional injections every 6 months. The study will compare this treatment to a placebo, a harmless substance with no medicine. Some participants who don't meet specific criteria will also receive the treatment openly.
- Duration: The study involves 6 initial treatments and 5 booster treatments over about 3 years.
- Eligibility: Participants must have completed standard breast cancer therapy and be at high risk of cancer returning.
- Requirements: Participants must be in good health, use effective birth control, and reside in the country where the study is conducted.
Before joining, it's important to talk to your doctor about the risks and benefits of participating. This study could help find better treatments for people with specific types of breast cancer.